Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34911336

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Future Oncol
Publication date
2022 Feb
First author
Cho BC

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Cho BC
      type
      Author
    2. name
      Felip E
      type
      Author
    3. name
      Hayashi H
      type
      Author
    4. name
      Thomas M
      type
      Author
    5. name
      Lu S
      type
      Author
    6. name
      Besse B
      type
      Author
    7. name
      Sun T
      type
      Author
    8. name
      Martinez M
      type
      Author
    9. name
      Sethi SN
      type
      Author
    10. name
      Shreeve SM
      type
      Author
    11. name
      Spira AI
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Cho BC
      type
      Author
    2. name
      Felip E
      type
      Author
    3. name
      Hayashi H
      type
      Author
    4. name
      Thomas M
      type
      Author
    5. name
      Lu S
      type
      Author
    6. name
      Besse B
      type
      Author
    7. name
      Sun T
      type
      Author
    8. name
      Martinez M
      type
      Author
    9. name
      Sethi SN
      type
      Author
    10. name
      Shreeve SM
      type
      Author
    11. name
      Spira AI
      type
      Author
    bibliography ids
    1. nci-bib-a4ca7cf3a585a28d167dcd61
    book metadata
    content sha256
    e0147632f7e1b56d506b474ccb46377afa102b71fccbc1b1c37fe369649785a1
    document type
    citation
    dois
    1. 10.2217/fon-2021-0923
    electronic publication date
    display
    2021 Dec 16
    precision
    day
    year
    2021
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:34911336
    immutable id
    pubmed:34911336@e0147632f7e1b56d506b474ccb46377afa102b71fccbc1b1c37fe369649785a1
    journal
    abbreviation
    Future Oncol
    issn electronic
    1744-8301
    issn print
    1479-6694
    issue
    6
    name
    Future oncology (London, England)
    nlm unique id
    101256629
    pages
    639-647
    volume
    18
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      34911336
      provenance
      batch id
      3f4d1914d2afe41e9e70
      provider
      NCBI PubMed ESummary
      record sha256
      4cb690b9d8b8faa813b172fc03b02b2b2a7b286dfa0bd433ddf82757631986a7
      response sha256
      0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
      retrieved at
      2026-09-09T23:48:06.522634+00:00
      publication date
      display
      2022 Feb
      precision
      month
      year
      2022
      publication types
      1. Clinical Trial Protocol
      2. Journal Article
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/34911336/
      title
      MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.

      Preserved source evidence · Not medical advice